Haloper

/ CTS

The dosage should be individualized according to the patient’s medical condition, clinical needs and responses. Usually start with a low dosage and then adjust to the suitable dosage. Please refer to the license holder for further details.

Management of psychotic disorders. Control of tics and vocal utterances of Tourette’s disorder in children.

Comatose states, CNS depression, Parkinson’s disease, known hypersensitivity to haloperidol, lesions of basal ganglia. In common with other neuroleptics, haloperidol has the potential to cause rare prolongation of the QT interval. Use of haloperidol is therefore contra-indicated in patients with clinically significant cardiac disorders e.g. recent acute myocardial infarction, uncompensated heart failure, arrhythmias treated with class IA and III antiarrhythmic medicinal products, QTc interval prolongation, history of ventricular arrhythmia or torsades de pointes clinically significant bradycardia, second or third degree heart block and uncorrected hypokalaemia. Haloperidol should not be used concomitantly with other QT prolonging drugs.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.